Business
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
NeoGenomics to Present New Research at ASCO Annual Meeting
About this update from Neogenomics, Inc.
[{"type":"text","content":"\nNeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it will showcase eight scientific abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130).\n\n\nThe abstracts demonstrate NeoGenomics' expanding capabilities across the company’s clinical oncology testing and data solutions, spanning hematologic malignancies, solid-tumor genomic profiling, the real-world impact of insurance coverage gaps on next-generation sequencing (NGS) testing, and the detection of circulating tumor DNA (ctDNA) through molecular residual disease (MRD). These findings include an online presentation on the utilization of RaDaR® ST in a colorectal cancer cohort, as reflected in an interim analysis from a collaboration with investigators at MD Anderson Cancer Center.\n\n\nTo support biopharma partners advancing ADCs, BiTES, bispecifics, radioligands, and targeted therapies, NeoGenomics will highlight new biomarkers, including B7-H3, CD137, EZH2, and PRMT5. The company is also developing a low-sample-input acute myeloid leukemia (AML) MRD flow assay designed to deliver higher sensitivity and faster turnaround times compared to currently available assays. This approach may enable more confident relapse risk prediction, therapeutic response assessment, and MRD endpoint tracking in hematologic trials, even when sample availability is limited.\n\n\nNeoGenomics will also debut its updated mission, partnering with physicians to deliver actionable insights that guide personalized treatment decisions and improve outcomes, and a new vision of a world where every cancer treatment decision is as personal as the patient. Both will be reflected throughout the booth, alongside the company's new tagline, 'Answers are in our DNA.'\n\n\n“A cancer diagnosis is the beginning of a long road, and NeoGenomics is committed to being there from first diagnosis through recurrence monitoring,” said Tony Zook, CEO of NeoGenomics. “The breadth of our ASCO research and a sharpened mission reflect our commitment to providing personalized answers for every cancer patient.\"\n\n\nPresentations and online abstracts at ASCO include:\n\nPoster #177: Bridging the Gap Between Clinical Utility and Coverage: Real-World Impact of Unreimbursed NGS T...